Technology | Magnetic Resonance Imaging (MRI) | December 11, 2017

Saturn X Gradient provides 30 percent increase in SNR during neuro MR exams; system also offers enhanced cardiac capabilities

Toshiba Vantage Galan 3T XGO Edition MRI Features New Advanced Gradient

MRI of the brain performed on the Galan 3T utilizing the 32-channel Head SPEEDER Coil


December 11, 2017 — Toshiba Medical, a Canon Group company, demonstrated the Vantage Galan 3T XGO Edition magnetic resonance imaging (MRI) with the all-new Saturn X Gradient, pending U.S. Food and Drug Administration (FDA) 510(k) clearance, at the 2017 Radiological Society of North America (RSNA) annual meeting, Nov. 26 – Dec. 1 in Chicago. The Saturn X Gradient features an advanced strength of 45 mT/m (milliTesla per meter) to offer healthcare providers fast, higher-resolution imaging, while continuing to deliver streamlined workflow and patient comfort.

The Saturn X Gradient on the Galan 3T XGO Edition comes with Toshiba Medical’s PUREGradient digital technology, which can provide up to 30 percent improved signal-to-noise ratio (SNR) for brain diffusion weighted imaging (DWI), resulting in even higher-resolution neuro images than previously offered. The Galan 3T XGO Edition offers the ability to conduct quick, comfortable and high-quality neuro imaging exams, and allows for faster sampling and higher-resolution images thanks to PURERF and Saturn technologies. This, combined with the ability to stack protocol sequences, results in quick neuro exams, enabling healthcare providers to produce higher resolution images for myriad neuro exams in under five minutes. The Galan 3T XGO Edition also offers Multiband SPEEDER technology, which allows for multiple slices to be acquired at the same time, reducing diffusion weighted imaging scan times by up to two times.

Beyond its neuro capabilities, the Galan 3T XGO Edition also offers enhanced cardiac imaging capabilities, including T1 mapping that utilizes MOdified Look-Locker Inversion recovery (MOLLI) sequence and allows providers to acquire a more quantitative characterization of myocardial tissue within a single breath hold. Additionally, Phase Sensitive Inversion Recovery (PSIR) in the heart provides improved contrast in late-enhanced imaging and eliminates the need for inversion time (TI) calibration scan, allowing cardiac exams to be completed with fewer breath holds and greater patient comfort.

For more information: www.medical.toshiba.com

 


Related Content

News | Breast Imaging

July 7, 2025 — SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, has ...

Time July 08, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | PET-CT

June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging ...

Time June 23, 2025
arrow
News | Cardiac Imaging

May 20, 2025 — Royal Philips has launched the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter ...

Time May 27, 2025
arrow
News | Pediatric Imaging

May 13, 2025-- GE HealthCare recently announced the U.S. Food and Drug Administration (FDA) has approved a pediatric ...

Time May 20, 2025
arrow
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
Subscribe Now